vs
Crexendo, Inc.（CXDO）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是Crexendo, Inc.的2.0倍（$35.5M vs $18.1M），Crexendo, Inc.净利率更高（6.7% vs -304.2%，领先311.0%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 11.2%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 12.4%）
Crexendo, Inc.是一家总部位于美国的云通信技术供应商，主要面向北美市场的中小企业提供统一通信即服务、呼叫中心解决方案、商业VoIP服务及相关协同办公工具。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CXDO vs RXRX — 直观对比
营收规模更大
RXRX
是对方的2.0倍
$18.1M
营收增速更快
RXRX
高出670.5%
11.2%
净利率更高
CXDO
高出311.0%
-304.2%
两年增速更快
RXRX
近两年复合增速
12.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.1M | $35.5M |
| 净利润 | $1.2M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 6.3% | -304.8% |
| 净利率 | 6.7% | -304.2% |
| 营收同比 | 11.2% | 681.7% |
| 净利润同比 | 140.2% | 39.6% |
| 每股收益（稀释后） | $0.03 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CXDORXRX
| Q4 25 | $18.1M | $35.5M | ||
| Q3 25 | $17.5M | $5.2M | ||
| Q2 25 | $16.6M | $19.2M | ||
| Q1 25 | $16.1M | $14.7M | ||
| Q4 24 | $16.2M | $4.5M | ||
| Q3 24 | $15.6M | $26.1M | ||
| Q2 24 | $14.7M | $14.4M | ||
| Q1 24 | $14.3M | $13.8M |
净利润CXDORXRX
| Q4 25 | $1.2M | $-108.1M | ||
| Q3 25 | $1.4M | $-162.3M | ||
| Q2 25 | $1.2M | $-171.9M | ||
| Q1 25 | $1.2M | $-202.5M | ||
| Q4 24 | $507.0K | $-178.9M | ||
| Q3 24 | $148.0K | $-95.8M | ||
| Q2 24 | $588.0K | $-97.5M | ||
| Q1 24 | $434.0K | $-91.4M |
毛利率CXDORXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率CXDORXRX
| Q4 25 | 6.3% | -304.8% | ||
| Q3 25 | 7.5% | -3327.6% | ||
| Q2 25 | 6.7% | -916.8% | ||
| Q1 25 | 7.2% | -1297.9% | ||
| Q4 24 | 3.9% | -4042.4% | ||
| Q3 24 | 0.9% | -377.1% | ||
| Q2 24 | 3.9% | -697.4% | ||
| Q1 24 | 3.4% | -698.4% |
净利率CXDORXRX
| Q4 25 | 6.7% | -304.2% | ||
| Q3 25 | 8.3% | -3135.3% | ||
| Q2 25 | 7.4% | -894.2% | ||
| Q1 25 | 7.3% | -1373.3% | ||
| Q4 24 | 3.1% | -3935.5% | ||
| Q3 24 | 0.9% | -367.5% | ||
| Q2 24 | 4.0% | -676.6% | ||
| Q1 24 | 3.0% | -662.4% |
每股收益（稀释后）CXDORXRX
| Q4 25 | $0.03 | $-0.17 | ||
| Q3 25 | $0.05 | $-0.36 | ||
| Q2 25 | $0.04 | $-0.41 | ||
| Q1 25 | $0.04 | $-0.50 | ||
| Q4 24 | $0.03 | $-0.56 | ||
| Q3 24 | $0.00 | $-0.34 | ||
| Q2 24 | $0.02 | $-0.40 | ||
| Q1 24 | $0.01 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | $114.0K | $9.6M |
| 股东权益账面价值 | $63.8M | $1.1B |
| 总资产 | $77.7M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.00× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资CXDORXRX
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
总债务CXDORXRX
| Q4 25 | $114.0K | $9.6M | ||
| Q3 25 | $236.0K | $11.9M | ||
| Q2 25 | $356.0K | $14.2M | ||
| Q1 25 | $475.0K | $16.4M | ||
| Q4 24 | $592.0K | $19.0M | ||
| Q3 24 | $709.0K | $20.5M | ||
| Q2 24 | $823.0K | $22.9M | ||
| Q1 24 | $937.0K | — |
股东权益CXDORXRX
| Q4 25 | $63.8M | $1.1B | ||
| Q3 25 | $61.3M | $1.0B | ||
| Q2 25 | $58.3M | $919.1M | ||
| Q1 25 | $55.2M | $933.9M | ||
| Q4 24 | $51.4M | $1.0B | ||
| Q3 24 | $49.5M | $524.6M | ||
| Q2 24 | $48.2M | $584.4M | ||
| Q1 24 | $46.8M | $401.2M |
总资产CXDORXRX
| Q4 25 | $77.7M | $1.5B | ||
| Q3 25 | $76.0M | $1.4B | ||
| Q2 25 | $71.4M | $1.3B | ||
| Q1 25 | $67.4M | $1.3B | ||
| Q4 24 | $64.9M | $1.4B | ||
| Q3 24 | $62.3M | $726.5M | ||
| Q2 24 | $59.6M | $775.9M | ||
| Q1 24 | $57.5M | $557.8M |
负债/权益比CXDORXRX
| Q4 25 | 0.00× | 0.01× | ||
| Q3 25 | 0.00× | 0.01× | ||
| Q2 25 | 0.01× | 0.02× | ||
| Q1 25 | 0.01× | 0.02× | ||
| Q4 24 | 0.01× | 0.02× | ||
| Q3 24 | 0.01× | 0.04× | ||
| Q2 24 | 0.02× | 0.04× | ||
| Q1 24 | 0.02× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.3M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | 0.0% | 3.5% |
| 现金转化率经营现金流/净利润 | 1.93× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流CXDORXRX
| Q4 25 | $2.3M | $-46.1M | ||
| Q3 25 | $4.4M | $-117.4M | ||
| Q2 25 | $1.3M | $-76.4M | ||
| Q1 25 | $1.2M | $-132.0M | ||
| Q4 24 | $2.2M | $-115.4M | ||
| Q3 24 | $1.6M | $-59.2M | ||
| Q2 24 | $2.7M | $-82.2M | ||
| Q1 24 | $-166.0K | $-102.3M |
自由现金流CXDORXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | $1.3M | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | $2.1M | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率CXDORXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | 7.7% | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | 13.2% | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度CXDORXRX
| Q4 25 | 0.0% | 3.5% | ||
| Q3 25 | 0.0% | 4.7% | ||
| Q2 25 | 0.1% | 16.4% | ||
| Q1 25 | 0.0% | 12.4% | ||
| Q4 24 | 0.2% | 28.6% | ||
| Q3 24 | 0.0% | 17.5% | ||
| Q2 24 | 0.0% | 8.2% | ||
| Q1 24 | 0.0% | 48.2% |
现金转化率CXDORXRX
| Q4 25 | 1.93× | — | ||
| Q3 25 | 3.05× | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 4.29× | — | ||
| Q3 24 | 10.95× | — | ||
| Q2 24 | 4.51× | — | ||
| Q1 24 | -0.38× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CXDO
| Services | $8.6M | 48% |
| Software Solution Segment | $8.3M | 46% |
| Products | $1.1M | 6% |
RXRX
暂无分部数据
